Search Result

Results for "

CT26

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Apoptosis (3) Autophagy (1) CD73 (1) CDK (1) CXCR (1) DNA-PK (1) G protein-coupled Bile Acid Receptor 1 (1) HDAC (3) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Integrin (1) Liposome (1) Microtubule/Tubulin (1) NF-κB (1) PARP (2) PD-1/PD-L1 (6) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (2) Ras (1) Sodium Channel (1) STAT (1) STING (3) Syk (1) TGF-β Receptor (1) β-catenin (2)
By Research Areas:	Cancer (32) Cardiovascular Disease (1) Inflammation/Immunology (10) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155971

VISTA-IN-2	Autophagy	Inflammation/Immunology Cancer
VISTA-IN-2 (Compound 1) is an inhibitor of V-domain Ig suppressor of T-cell activation (VISTA). VISTA-IN-2 induces VISTA degradation in cells through an autophagic mechanism. VISTA-IN-2 rescues VISTA-mediated immunosuppression, and enhances antitumor activity of immune cells. VISTA-IN-2 also activates the antitumor immunity and inhibits tumor growth in a CT26 mouse model .

HY-155457

Enpp-1-IN-19	Phosphodiesterase (PDE) STING	Cancer
Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC₅₀=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence .

HY-132192

PD-1/PD-L1-IN-9 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-132192A

PD-1/PD-L1-IN-9 hydrochloride 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-P10439

CVRARTR	PD-1/PD-L1	Cancer
CVRARTR is an antagonist for programmed cell death ligand-1 (PD-L1) with K_D of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model .

HY-139716

IMD-catechol	NF-κB	Inflammation/Immunology
IMD-catechol is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves efficacy in a CT26 mouse colon carcinoma tumor model while eliciting minimal adjuvant toxicity.

HY-164360

αVβ8-IN-1	Integrin	Inflammation/Immunology Cancer
αVβ8-IN-1 is a αVβ8 integrin inhibitor. αVβ8-IN-1 has been shown to inhibit the growth of tumors such as EMT6, CT26, KPC, and TKCC-10. αVβ8-IN-1 can be used in research related to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and tumors .

HY-162766

Antitumor agent-184	Others	Cancer
Antitumor agent-184 (compound 12aa) induces cell apoptosis, with the IC₅₀s of 2.35 μM, 7.32 μM and 10.31 μM in B16-F10 cells, 4T1 cells and CT26 cells, respectively .

HY-161677

PD-L1/CD-73-IN-1	PD-1/PD-L1 CD73	Inflammation/Immunology Cancer
PD-L1/CD-73-IN-1 (compound CC-5) is PD-L1/CD73 inhibitor with IC₅₀ values of 6 nM and 0.773 μM to PD-L1 and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro .

HY-163719

PARP7-IN-22	PARP	Cancer
PARP7-IN-22 (XLY-1) is a PARP7 inhibitor with an IC₅₀ of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy .

HY-153546

STING agonist-31	STING	Cancer
STING agonist-31 is a STING agonist, with EC₅₀ values of 0.24 and 39.51 μM for h-STING and m-STING. STING agonist-31 has antitumor efficiency .

HY-128679

TBK1/IKKε-IN-5	IKK	Cancer
TBK1/IKKε-IN-5 (compound 1) is an orally active TBK1 and IKKε dual inhibitor, with IC₅₀ values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to PD-1 and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity .

HY-B0575

Triamterene 4 Publications Verification	Sodium Channel G protein-coupled Bile Acid Receptor 1	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Triamterene blocks epithelial Na ⁺ channel (ENaC) in a voltage-dependent manner, which used as a mild diuretic. Triamterene is an inhibitor of the TGR5 receptor .

HY-139693

PTPN22-IN-1 1 Publications Verification	Phosphatase	Inflammation/Immunology Cancer
PTPN22-IN-1 is a potent PTPN22 inhibitor (IC₅₀=1.4 µM; K_i=0.50 µM). PTPN22-IN-1 exhibits >7-10 fold selectivity for PTPN22 over similar phosphatases. PTPN22-IN-1 augments antitumor immune responses . From WO2021007491A1 compound L-1.

HY-143325

A2AAR/HDAC-IN-2	HDAC Adenosine Receptor	Cancer
A2AAR/HDAC-IN-2 is a potent A_2AAR/HDAC dual inhibitor, with good binding affinity for A_2AAR (K_i=10.3 nM) and good inhibitory activity against HDAC1 (IC₅₀=18.5 nM). A2AAR/HDAC-IN-2 can be used in study of antitumor .

HY-163081

PARP7-IN-17	PARP	Cancer
PARP7-IN-17 is a potent inhibitor of PARP7 with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

HY-143324

A2AAR/HDAC-IN-1	HDAC Adenosine Receptor	Cancer
A2AAR/HDAC-IN-1 (compound 14c) is an orally active, potent and balanced A_2AAR/HDAC dual inhibitor, with a K_i of 163.5 nM for A_2AAR and an IC₅₀ of 145.3 nM for HDAC1. A2AAR/HDAC-IN-1 shows anticancer activity .

HY-145280

IDO1/2-IN-1	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IDO1/2-IN-1 (compound 4t) is the first potent IDO1/IDO2 dual inhibitor with IC₅₀s of 28 nM and 144 nM for IDO1 and IDO2, respectively. IDO1/2-IN-1 exhibits antitumor activies. Orally active .

HY-144661

KRAS G12D inhibitor 14	Ras Apoptosis	Cancer
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a K_D of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D .

HY-145280A

IDO1/2-IN-1 hydrochloride	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IDO1/2-IN-1 hydrochloride (compound 4t) is the first potent IDO1/IDO2 dual inhibitor with IC₅₀s of 28 nM and 144 nM for IDO1 and IDO2, respectively. IDO1/2-IN-1 hydrochloride exhibits antitumor activies. Orally active .

HY-147834

STING agonist-9	STING	Cancer
STING agonist-9 (Compound 45) is a potent STING agonist with an EC₅₀ of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity .

HY-147949

SKLB0565	Microtubule/Tubulin Apoptosis	Cancer
SKLB0565 is a potent tubulin inhibitor. SKLB0565 shows significant anti-proliferative activity against CRC (colorectal carcinoma) cell lines, with IC₅₀ values ranging from 0.012 μM to 0.081 μM. SKLB0565 causes G2/M phase arrest and mitochondria-mediated intrinsic apoptosis. SKLB0565 inhibits cell migration and disrupted the tube formation of HUVECs .

HY-122891

SB02024	PI3K CXCR STAT	Cancer
SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity .

HY-162357

PD-L1-IN-5	PD-1/PD-L1	Cancer
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor, with the IC₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo .

HY-151066

BMS-1233	PD-1/PD-L1	Cancer
BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC₅₀ of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model .

HY-163767

Antitumor agent-171	β-catenin	Inflammation/Immunology Cancer
Antitumor agent-171 (Compound 35) is an inhibitor for β-catenin/BCL9 interaction with IC₅₀ of 1.61 μM. Antitumor agent-171 exhibits high affinity to β-catenin with K_d of 0.63 μM. Antitumor agent-171 inhibits the gene expression of axin2 with IC₅₀ of 0.84 μM. Antitumor agent-171 inhibits cell viability of HCT116 with IC₅₀ of 4.39 μM. Antitumor agent-171 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .

HY-163768

Antitumor agent-172	β-catenin	Inflammation/Immunology Cancer
Antitumor agent-172 (Compound 28) is an inhibitor for β-catenin/BCL9 interaction with IC₅₀ of 3.92 μM. Antitumor agent-172 exhibits high affinity to β-catenin with K_d of 82 nM. Antitumor agent-172 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .

HY-158166

DNA-PK-IN-13	DNA-PK	Inflammation/Immunology Cancer
DNA-PK-IN-13 (Compound SK10) is a DNA-PK inhibitor that exhibits potent inhibitory activity (IC₅₀= 0.11 nM). DNA-PK-IN-13 regulates tumor cell proliferation by decreasing the expression level of γH2A.X and enhancing the sensitivity of tumor cells to chemotherapeutic agents. DNA-PK-IN-13 is suitable for oncology studies .

HY-136198

SRX3207	Syk PI3K	Cancer
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC₅₀ values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression .

HY-144395

HDAC6-IN-4	HDAC Apoptosis	Inflammation/Immunology Cancer
HDAC6-IN-4 (C10) is a potent, orally active and highly selective HDAC6 inhibitor with an IC₅₀ value of 23 nM. HDAC6-IN-4 induces cancer cells apoptosis and shows significant antitumor efficacy, without obvious toxicity .

HY-143889

Senexin C	CDK	Cancer
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .

HY-136244

PF-06952229 1 Publications Verification	TGF-β Receptor	Cancer
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer .

HY-151506

Phospholipid PL1	Liposome	Cancer
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .

Cat. No.	Product Name	Type

HY-151506

Phospholipid PL1	Drug Delivery
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .

Cat. No.	Product Name	Target	Research Area

HY-P4193

AH1	Peptides	Inflammation/Immunology
AH1 is an immunodominant antigen derived from the gp70 product of an endogenous MuLV. AH1 behaves as the CTL-immunodominant epitope of CT26 colon carcinoma .

HY-P10439

CVRARTR	PD-1/PD-L1	Cancer
CVRARTR is an antagonist for programmed cell death ligand-1 (PD-L1) with K_D of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model .

Cat. No.	Product Name		Classification

HY-151506

Phospholipid PL1		Phospholipids
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: